Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "Gastrointestinal" returned 9 results:

A Phase 1 Study of Ly2801653 in Patients with Advanced Cancer
Principal Investigator(s): Randall Holcombe

A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome
Principal Investigator(s): Dr. Richard Warner

A phase 2 randomized multicenter study of PEGPH20 (hyaluronidase) combined with nab-paclitaxel plus gemcitabine compared with nab-paclitaxel plus gemcitabine in subjects with stage IV previously untreated pancreatic cancer
Principal Investigator(s): Randall Holcombe

A Phase 2B, randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 Compared to Chemotherapy or to CRS-207 Alone in Adults with Previously-Treated Metastatic Pancreatic Adenocarcinoma
Principal Investigator(s): Dr. Max Sung

A phase III study of FOLFIRINOX with or without HyperAcute®-Pancreas (algenpantucel-l) Immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer
Principal Investigator(s): Daniel Labow

A feasibility and adherence study of personalized therapeutic interventions targeting minimal residual disease following adjuvant colon cancer therapy
Principal Investigator(s): Dr. Randall Holcombe

A phase II/III trial of neoadjuvant FOLFOX, with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total mesorectal excision
Principal Investigator(s): Celina Ang

Genistein Combined with FOLFOX or FOLFOX-Avastin for treatment of Metastatic Colorectal Cancer: Phase I/II Pilot Study
Principal Investigator(s): Randall Holcombe

A phase III study of chemotherapy and chemoradiotherapy with or without hyperacute- pancreatic vaccine in subjects with surgically resected pancreatic cancer
Principal Investigator(s): Daniel M. Labow